FDA halts MS drug trial in wake of Tysabri

GlaxoSmithKline said on Wednesday U.S. regulators had halted clinical trials on multiple sclerosis drugs in the same class as recently withdrawn treatment Tysabri, including its experimental product '699.

Top News Article | Reuters.com

BioBOOM Op/Ed: Not all bad news is bad for the whole Biotech Market. Industry analysts said makers of interferon-based MS drugs, including Switzerland's Serono, stood to gain from any further delays to newer types of treatment -- and Serono shares advanced as much as 1.3 percent. Yet we think this time or poor news which will get better, presents a possible buying opportunity long term. The Baby Boomers are coming and they are gonna need lots and lots of meds. Although we wait to see pre-screening models and individualized medicine become the new paradiqm.

No comments:

Blog Archive